JoinClinicalTrials.com

• A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy

  NCT04036019

  Condition:   B Cell Lymphoma
  Intervention:   Biological: CD20-directed CAR-T cells
  Sponsors:   Shanghai Tongji Hospital, Tongji University School of Medicine;   Cellular Biomedicine Group Ltd.
  Recruiting
• Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas

  NCT03920631

  Condition:   B Cell Lymphomas
  Interventions:   Drug: Nivolumab;   Biological: Microtransplantation
  Sponsor:   Ahmed Galal, MD
  Recruiting
• INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

  NCT03424122

  Condition:   B-cell Lymphoma
  Interventions:   Drug: Parsaclisib;   Drug: Rituximab;   Drug: Bendamustine;   Drug: Ibrutinib
  Sponsor:   Incyte Corporation
  Recruiting
• Study of TG-1801 in Subjects With B-Cell Lymphoma

  NCT03804996

  Condition:   B-Cell Lymphoma
  Intervention:   Drug: TG-1801
  Sponsor:   TG Therapeutics, Inc.
  Recruiting
• Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma.

  NCT03929107

  Condition:   B Cell Lymphoma
  Intervention:   Biological: Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells
  Sponsors:   Wenbin Qian;   Zhejiang Provincial Tongde Hospital
  Recruiting
• Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma

  NCT03761056

  Condition:   B-cell Lymphoma
  Interventions:   Biological: Axicabtagene Ciloleucel;   Drug: Fludarabine;   Drug: Cyclophosphamide
  Sponsor:   Kite, A Gilead Company
  Recruiting
• A Study to Investigate BGB-3111 in Chinese Patients With B-cell Lymphoma

  NCT03189524

  Condition:   B-cell Lymphoma
  Intervention:   Drug: BGB-3111
  Sponsor:   BeiGene
  Recruiting
• A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients

  NCT03670888

  Condition:   B Cell Lymphoma
  Interventions:   Biological: JHL1101;   Biological: Rituximab
  Sponsor:   JHL Biotech, Inc.
  Not yet recruiting
• Cell Free DNA in Mature B-cell Lymphoma

  NCT04088422

  Condition:   Mature B-Cell Lymphoma
  Intervention:   Procedure: peripheral blood collection
  Sponsor:   Ruijin Hospital
  Recruiting
• A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP

  NCT02741388

  Condition:   B-cell Lymphoma
  Interventions:   Drug: selinexor;   Drug: Rituximab;   Drug: Dexamethasone;   Drug: Oxaliplatin;   Drug: Cisplatin;   Drug: Cytarabine;   Drug: Gemcitabine
  Sponsors:   The Lymphoma Academic Research Organisation;   Karyopharm Therapeutics Inc
  Recruiting
• Study of Anti-CD19 iCAR NK Cells in Relapsed and Refractory B Cell Lymphoma

  NCT03824951

  Condition:   Refractory B-Cell Lymphoma
  Intervention:   Biological: Anti-CD19 iCAR NK Cells
  Sponsors:   Allife Medical Science and Technology Co., Ltd.;   Beijing Cancer Hospital
  Not yet recruiting
• Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

  NCT03824964

  Condition:   Refractory B-Cell Lymphoma
  Intervention:   Biological: Anti-CD19/CD22 CAR NK Cells
  Sponsors:   Allife Medical Science and Technology Co., Ltd.;   Beijing Cancer Hospital
  Not yet recruiting
• Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

  NCT03692767

  Condition:   Refractory B-Cell Lymphoma
  Intervention:   Biological: Anti-CD22 CAR NK Cells
  Sponsor:   Allife Medical Science and Technology Co., Ltd.
  Not yet recruiting
• Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

  NCT03690310

  Condition:   Refractory B-Cell Lymphoma
  Intervention:   Biological: Anti-CD19 CAR NK Cells
  Sponsor:   Allife Medical Science and Technology Co., Ltd.
  Not yet recruiting
• Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma

  NCT02767674

  Condition:   Diffuse Large B Cell Lymphoma
  Interventions:   Drug: Rituximab;   Drug: Gemcitabine;   Drug: Oxaliplatin;   Drug: Cyclophosphamide;   Drug: Epirubicin Injectable Product;   Drug: Vindesine;   Drug: Prednisone
  Sponsor:   The First Affiliated Hospital with Nanjing Medical University
  Recruiting
• Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)

  NCT04148742

  Condition:   Non-Hodgkin's B-cell Lymphoma
  Intervention:   Drug: DZD9008
  Sponsor:   Dizal (Jiangsu) Pharmaceutical Co., Ltd.
  Not yet recruiting
• Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma

  NCT02733380

  Condition:   Diffuse Large B-cell Lymphoma
  Interventions:   Drug: Chidamide;   Drug: Vinorelbine;   Drug: Liposomal Doxorubicin or mitoxantrone;   Drug: Dexamethasone;   Drug: Thalidomide
  Sponsor:   Henan Cancer Hospital
  Recruiting
• Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients

  NCT03630159

  Condition:   Diffuse Large B-cell Lymphoma
  Interventions:   Biological: Tisagenlecleucel;   Drug: Pembrolizumab
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients

  NCT03876028

  Condition:   Diffuse Large B-cell Lymphoma
  Interventions:   Biological: Tisagenlecleucel;   Drug: Ibrutinib
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma

  NCT03704298

  Condition:   Refractory Large B-cell Lymphoma
  Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Axicabtagene Ciloleucel;   Biological: Utomilumab
  Sponsors:   Kite, A Gilead Company;   Pfizer
  Recruiting
• Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Either Rituximab or Lenalidomide in Participants With Refractory Large B-Cell Lymphoma (ZUMA-14)

  NCT04002401

  Condition:   Refractory Large B-cell Lymphoma
  Interventions:   Biological: Axicabtagene Ciloleucel;   Drug: Rituximab;   Drug: Lenalidomide;   Drug: Fludarabine;   Drug: Cyclophosphamide
  Sponsor:   Gilead Sciences
  Recruiting
• CART-19 Cells for R/R B-cell Lymphoma

  NCT03391726

  Condition:   Relapsed or Refractory B-cell Lymphoma
  Intervention:   Other: CART-19 cells
  Sponsor:   Fujian Medical University
  Recruiting
• Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma

  NCT04056975

  Condition:   Relapsed or Refractory B-cell Lymphoma
  Intervention:   Biological: Recombinant Anti-CD19m-CD3 Antibody Injection
  Sponsors:   Generon (Shanghai) Corporation Ltd.;   Beijing Cancer Hospital
  Not yet recruiting
• Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma

  NCT03513601

  Condition:   Diffuse Large B Cell Lymphoma
  Interventions:   Drug: (R)-CHOP regimen;   Drug: (R)-CVP regimen
  Sponsor:   Mingzhi Zhang
  Recruiting
• Design of New Personalized Therapeutic Approaches for Diffuse Large B-cell Lymphoma

  NCT03797170

  Condition:   Diffuse Large B Cell Lymphoma
  Intervention:   Other: Gut microbiota samples
  Sponsor:   University of Bologna
  Recruiting
• Mature B-Cell Lymphoma And Leukemia Study III

  NCT01046825

  Condition:   Mature B-Cell Lymphoma
  Interventions:   Drug: COPAD;   Drug: COP, COPD M3, CYM;   Drug: COP, COPADM8, CYVE
  Sponsor:   St. Jude Children's Research Hospital
  Recruiting
• CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

  NCT04026100

  Condition:   Diffuse Large B-cell Lymphoma
  Intervention:   Biological: CTA101
  Sponsors:   The First Affiliated Hospital with Nanjing Medical University;   Nanjing Bioheng Biotech Co., Ltd.
  Not yet recruiting
• Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma

  NCT03719560

  Condition:   Diffuse Large B Cell Lymphoma
  Interventions:   Drug: Methotrexate;   Drug: Cytarabine
  Sponsor:   Brown University
  Not yet recruiting
• Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma

  NCT03208556

  Condition:   Relapsed or Refractory B-cell Lymphoma
  Interventions:   Biological: iPD1 CD19 eCAR T cells;   Drug: Fludarabine and cyclophosphamide
  Sponsors:   Peking University;   Marino Biotechnology Co., Ltd.
  Recruiting
• Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma

  NCT03576443

  Condition:   Diffuse Large B Cell Lymphoma
  Intervention:   Drug: Idelalisib
  Sponsor:   Nordic Lymphoma Group
  Recruiting
• A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma

  NCT03579082

  Condition:   Diffuse Large B Cell Lymphoma
  Intervention:   Drug: Decitabine
  Sponsor:   Mingzhi Zhang
  Recruiting
• A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients

  NCT03650933

  Condition:   Diffuse Large B-Cell Lymphoma, Unspecified Site
  Interventions:   Biological: G-CHOP;   Biological: R-CHOP
  Sponsor:   Nanjing Yoko Biomedical Co., Ltd.
  Not yet recruiting
• Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma

  NCT03681535

  Condition:   Diffuse Large B Cell Lymphoma
  Intervention:   Radiation: Radiation Therapy
  Sponsor:   Duke University
  Recruiting
• Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL)

  NCT03104478

  Condition:   Diffuse Large B Cell Lymphoma
  Intervention:   Procedure: Biological samples collection
  Sponsor:   The Lymphoma Academic Research Organisation
  Recruiting
• A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  NCT03873025

  Condition:   Diffuse Large B Cell Lymphoma
  Intervention:   Combination Product: Pembrolizumab and CXD101
  Sponsors:   University College, London;   Celleron Therapeutics Ltd.;   Merck Sharp & Dohme Corp.
  Not yet recruiting
• A Trial to Evaluate the Efficacy and Safety of MOR208 With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

  NCT02763319

  Condition:   Diffuse Large B-cell Lymphoma
  Interventions:   Drug: Rituximab (RTX);   Drug: MOR208;   Drug: Bendamustine (BEN)
  Sponsors:   MorphoSys AG;   ICON Clinical Research
  Recruiting
• Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma

  NCT03399513

  Condition:   Diffuse Large B Cell Lymphoma
  Interventions:   Drug: Ibrutinib Oral Capsule [Imbruvica];   Drug: R-CHOEP chemotherapy
  Sponsors:   University Hospital Muenster;   Janssen-Cilag G.m.b.H
  Recruiting
• A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma

  NCT03688152

  Conditions:   Relapsed Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
  Interventions:   Drug: INCB053914;   Drug: INCB050465
  Sponsor:   Incyte Corporation
  Recruiting
• Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)

  NCT03777085

  Condition:   Diffuse Large B-cell Lymphoma
  Interventions:   Drug: TQB2303;   Drug: Rituximab
  Sponsor:   Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  Recruiting
• A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  NCT04182204

  Condition:   Diffuse Large B-Cell Lymphoma
  Interventions:   Drug: Polatuzumab Vedotin;   Drug: Rituximab;   Drug: Gemcitabine;   Drug: Oxaliplatin
  Sponsor:   Hoffmann-La Roche
  Recruiting
• 18F-FDG PET Scan and MRI Diffusion.Evaluation of the Early Therapeutic Response of Diffuse Large B-cell Lymphoma

  NCT03121456

  Condition:   Diffuse Large B Cell Lymphoma
  Interventions:   Other: 18F-FDG PET SCAN;   Other: MRI DIFFUSION
  Sponsor:   Centre Antoine Lacassagne
  Recruiting
• A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)

  NCT03670901

  Condition:   Diffuse Large B-Cell Lymphoma
  Interventions:   Biological: JHL1101;   Biological: MabThera
  Sponsor:   JHL Biotech, Inc.
  Not yet recruiting
• Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma

  NCT02753062

  Condition:   Diffuse Large B Cell Lymphoma
  Intervention:   Drug: bendamustine, rituximab
  Sponsors:   Asan Medical Center;   Cheolwon Suh
  Recruiting
• A Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Therapy in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma Who Are Unable to Tolerate Full-Dose Chemotherapy

  NCT03677154

  Condition:   Diffuse Large B-cell Lymphoma
  Interventions:   Drug: Mosunetuzumab;   Drug: Tocilizumab
  Sponsor:   Hoffmann-La Roche
  Recruiting
• Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma

  NCT04002622

  Condition:   Relapsed or Refractory Primary Mediastinal B-cell Lymphoma (rrPMBCL)
  Intervention:   Drug: TQB2450
  Sponsor:   Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  Recruiting
• Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Diffuse Large B-cell Lymphoma

  NCT02449265

  Condition:   Diffuse Large B-cell Lymphoma
  Interventions:   Radiation: Consolidation involved-site radiotherapy (ISRT);   Radiation: Consolidation involved-field radiotherapy (IFRT);   Drug: cyclophosphamide;   Drug: doxorubicin;   Drug: vincristine;   Drug: prednisone
  Sponsor:   Wuhan University
  Recruiting
• A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

  NCT03274492

  Condition:   Diffuse Large B-Cell Lymphoma
  Interventions:   Drug: Polatuzumab Vedotin;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Vincristine Placebo;   Drug: Prednisone;   Drug: Polatuzumab vedotin Placebo
  Sponsor:   Hoffmann-La Roche
  Recruiting
• The Palliative Benefit of Involved-site Radiotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma

  NCT02449278

  Condition:   Diffuse Large B-cell Lymphoma
  Interventions:   Radiation: Consolidation involved-site radiotherapy (ISRT);   Radiation: Consolidation involved-field radiotherapy (IFRT);   Drug: cyclophosphamide;   Drug: doxorubicin;   Drug: vincristine;   Drug: prednisone
  Sponsor:   Wuhan University
  Recruiting
• Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to Autologous Stem Cell Transplantation

  NCT02692248

  Condition:   Diffuse Large B-Cell Lymphoma
  Interventions:   Drug: Ibrutinib;   Drug: Rituximab;   Drug: Gemcitabine;   Drug: Oxaliplatin;   Drug: Dexamethasone
  Sponsors:   Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea;   Janssen-Cilag, S.A.
  Recruiting
• Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

  NCT03936153

  Condition:   Diffuse Large B-cell Lymphoma (DLBCL)
  Intervention:   Drug: abexinostat
  Sponsor:   Xynomic Pharmaceuticals, Inc.
  Not yet recruiting
• KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma

  NCT02471911

  Condition:   Diffuse Large B-Cell Lymphoma
  Interventions:   Drug: KPT-330;   Drug: Rituximab;   Drug: Etoposide;   Drug: Carboplatin;   Drug: Ifosfamide;   Drug: Dexamethasone
  Sponsors:   Weill Medical College of Cornell University;   Karyopharm Therapeutics Inc
  Recruiting
• A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

  NCT03992339

  Condition:   Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
  Intervention:   Drug: ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle
  Sponsor:   Antengene Corporation
  Not yet recruiting
• A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

  NCT02957019

  Condition:   Diffuse Large B-cell Lymphoma (DLBCL)
  Interventions:   Drug: L19-IL2 - Ph I;   Drug: L19-IL2 at RD - Ph II;   Drug: Rituximab
  Sponsor:   Philogen S.p.A.
  Recruiting
• Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

  NCT02405078

  Conditions:   Recurrent Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
  Interventions:   Drug: Chemotherapy;   Procedure: Computed Tomography;   Drug: Fludeoxyglucose F-18;   Procedure: Positron Emission Tomography
  Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
  Recruiting
• Safety and Efficiency Study of CD19-PD1-CART Cell in Relapsed/Refractory B Cell Lymphoma

  NCT04163302

  Condition:   Lymphoma, B-Cell
  Intervention:   Biological: CD19-PD1-CART Cell
  Sponsor:   Chinese PLA General Hospital
  Recruiting
• Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma

  NCT03994913

  Conditions:   Refractory B-Cell Non-Hodgkin Lymphoma;   Relapsed B-cell Non-Hodgkin Lymphoma
  Intervention:   Biological: CAR-CD19 T Cells
  Sponsors:   Carsgen Therapeutics, Ltd.;   First Affiliated Hospital of Zhejiang University;   RenJi Hospital
  Recruiting
• Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell Lymphoma

  NCT03880279

  Condition:   Lymphoma, B-Cell
  Intervention:   Biological: TAC01-CD19
  Sponsor:   Triumvira Immunologics, Inc.
  Not yet recruiting
• Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

  NCT04161248

  Condition:   Lymphoma, B-Cell
  Interventions:   Drug: Venetoclax;   Drug: RiTUXimab Injection;   Drug: Rituximab SC;   Drug: Gemcitabine;   Drug: Dexamethasone;   Drug: Cisplatin
  Sponsors:   Canadian Cancer Trials Group;   Roche Pharma AG;   AbbVie
  Not yet recruiting
• Study of the Safety, Tolerability and Pharmacokinetics of HZ-A-018 in Patients With B Cell Lymphoma

  NCT04173455

  Condition:   Lymphoma, B-Cell
  Intervention:   Drug: HZ-A-018
  Sponsors:   First Affiliated Hospital of Zhejiang University;   Hangzhou HeZheng Pharmaceutical Co., Ltd
  Recruiting
• Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

  NCT02443077

  Conditions:   Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type;   Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
  Interventions:   Procedure: Autologous Bone Marrow Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Pharmacogenomic Study;   Other: Placebo Administration
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Indolent Non Follicular Lymphomas Prognostic Project

  NCT02904577

  Condition:   Indolent B-Cell Lymphomas
  Intervention:   Other: Any treatment, watch and wait policy included
  Sponsor:   Fondazione Italiana Linfomi ONLUS
  Recruiting
• Improving the Outcome of High-risk Aggressive B-cell Lymphoma Patients With Nivolumab Maintenance Therapy

  NCT03569696

  Condition:   Lymphoma, B-Cell
  Intervention:   Biological: nivolumab
  Sponsor:   Meirav Kedmi MD
  Recruiting
• Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma

  NCT02992834

  Condition:   Lymphoma, B Cell
  Interventions:   Biological: IL-2 pre-treated CD19 cells;   Biological: IL-7/IL-15 pre-treated CD19 cells
  Sponsor:   jiangjingting
  Not yet recruiting
• Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas

  NCT02891590

  Conditions:   Chronic Lymphocytic Leukemia;   B-cell Lymphomas
  Intervention:   Drug: DTRMWXHS-12
  Sponsor:   Zhejiang DTRM Biopharma
  Recruiting
• Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma

  NCT02474550

  Conditions:   Diffuse Large B Cell Lymphoma;   Neutropenia, Febrile
  Intervention:  
  Sponsor:   Ajou University School of Medicine
  Recruiting
• Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents

  NCT03206671

  Condition:   Mature B-cell Non-Hodgkin Lymphoma
  Interventions:   Drug: Rituximab window;   Drug: Additional doses of Rituximab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin hydrochloride;   Drug: Vindesine Sulfate;   Drug: Etoposide;   Drug: Ifosfamide;   Drug: Methotrexate;   Drug: Prednisolone;   Drug: Vincristine
  Sponsors:   University Hospital Muenster;   Deutsche Krebshilfe e.V., Bonn (Germany)
  Recruiting
• A Combination of Rituximab and Varlilumab Immunotherapy in Patients With B-cell Lymphoma

  NCT03307746

  Condition:   B Cell Lymphoma
  Intervention:   Drug: Varlilumab
  Sponsors:   University Hospital Southampton NHS Foundation Trust;   University Hospital Plymouth NHS Trust;   The Christie NHS Foundation Trust;   Oxford University Hospitals NHS Trust;   Celldex Therapeutics;   Cancer Research UK
  Recruiting
• Study of Roflumilast in Combination With Standard Chemotherapy for High-risk Diffuse Large B-cell Lymphoma

  NCT03458546

  Condition:   Lymphoma, B-Cell
  Intervention:   Drug: Roflumilast
  Sponsor:   The University of Texas Health Science Center at San Antonio
  Recruiting
• ctDNA and Metabolites in CSF as Early Biomarkers of Secondary CNS Involvement in Diffuse Large B-cell Lymphoma

  NCT04112238

  Conditions:   Diffuse Large B Cell Lymphoma;   Central Nervous System Metastasis
  Intervention:  
  Sponsors:   Herlev Hospital;   Weill Medical College of Cornell University
  Recruiting
• A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

  NCT02600897

  Condition:   Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma
  Interventions:   Drug: Lenalidomide;   Drug: Obinutuzumab;   Drug: Polatuzumab Vedotin;   Drug: Rituximab
  Sponsor:   Hoffmann-La Roche
  Recruiting
• DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma

  NCT03837873

  Conditions:   Diffuse Large B Cell Lymphoma;   High-grade B-cell Lymphoma;   Transformed Lymphoma
  Interventions:   Drug: Rituximab;   Drug: Etoposide;   Drug: Vincristine;   Drug: Doxorubicin;   Drug: Dexamethasone;   Drug: Cyclophosphamide;   Drug: Lenalidomide;   Drug: Cisplatin;   Drug: Cytarabine
  Sponsor:   Institute of Hematology & Blood Diseases Hospital
  Recruiting
• Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma

  NCT03892525

  Conditions:   Recurrent B-Cell Non-Hodgkin Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma
  Interventions:   Drug: Selicrelumab;   Drug: Atezolizumab
  Sponsors:   The Lymphoma Academic Research Organisation;   Roche Pharma AG
  Recruiting
• Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma

  NCT03939182

  Conditions:   Diffuse Large B-cell Lymphoma;   Mantle Cell Lymphoma
  Interventions:   Drug: Abexinostat;   Drug: Ibrutinib
  Sponsors:   Memorial Sloan Kettering Cancer Center;   Janssen Scientific Affairs, LLC;   Xynomic Pharmaceuticals, Inc.
  Recruiting
• An Observational Study on Evaluating the Efficacy and Safety of Preemptive Antiviral Therapy With Tenofovir in HBsAg-positive Patients With Diffuse Large B-cell Lymphoma Receiving Rituximab-CHOP Chemotherapy (SPEED Study)

  NCT02354846

  Condition:   B-cell Lymphoma
  Intervention:  
  Sponsor:   Yonsei University
  Recruiting
• Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma

  NCT02660710

  Conditions:   Diffuse Large B-cell Lymphoma;   HIV
  Intervention:   Drug: R-CHOP
  Sponsors:   UNC Lineberger Comprehensive Cancer Center;   John E. Fogarty International Center (FIC);   National Institutes of Health (NIH);   National Cancer Institute (NCI)
  Recruiting
• CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia

  NCT03854994

  Conditions:   B Cell Lymphoma;   B-cell Acute Lymphoblastic Leukemia
  Intervention:   Biological: Anti-CD19 CAR-T Cells Injection
  Sponsors:   Yan'an Affiliated Hospital of Kunming Medical University;   KAEDI
  Recruiting
• Exosomes and Immunotherapy in Non-Hodgkin B-cell Lymphomas

  NCT03985696

  Condition:   Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL)
  Intervention:   Other: blood sample
  Sponsor:   University Hospital, Limoges
  Recruiting
• Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas

  NCT02900716

  Conditions:   Chronic Lymphocytic Leukemia;   B-Cell Lymphoma
  Interventions:   Drug: DTRMWXHS-12;   Drug: DTRM-505;   Drug: DTRM-555
  Sponsor:   Zhejiang DTRM Biopharma
  Recruiting
• A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHL

  NCT03060850

  Condition:   B-cell Lymphoma
  Intervention:   Drug: AC0010MA
  Sponsor:   Hangzhou ACEA Pharmaceutical Research Co., Ltd.
  Recruiting
• Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma

  NCT03281551

  Conditions:   B-cell Acute Lymphoblastic Leukemia;   B-cell Lymphoma
  Intervention:   Drug: PZ01 CAR-T cells
  Sponsors:   Pinze Lifetechnology Co. Ltd.;   Chinese Academy of Sciences;   Navy General Hospital, Beijing
  Recruiting
• Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

  NCT02570542

  Conditions:   Diffuse Large B-cell Lymphoma (DLBCL);   Relapsed Diffuse Large B-cell Lymphoma (DLBCL);   Refractory Diffuse Large B-cell Lymphoma (DLBCL)
  Interventions:   Procedure: leukapheresis;   Drug: Plerixafor;   Drug: carmustine, etoposide, cytarabine, melphalan;   Procedure: Autologous Stem Cell Transplantation
  Sponsors:   Memorial Sloan Kettering Cancer Center;   Columbia University;   NorthShore University HealthSystem;   University of Rochester;   Medical College of Wisconsin;   University of Nebraska;   Sanofi;   University Hospitals Seidman Cancer Center
  Recruiting
• CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma

  NCT03881761

  Conditions:   B-Cell Lymphoma Stage I;   Refractory;   Relapsed
  Intervention:   Biological: CD19/CD20 bispecific CAR-T cells
  Sponsors:   Henan Cancer Hospital;   Henan Hualong Biotechnology Company
  Recruiting
• Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2

  NCT03129828

  Condition:   Diffuse Large B Cell Lymphoma
  Intervention:   Drug: Ibrutinib and Bortezomib + R-CHOP
  Sponsors:   Prof. Dr. Clemens Schmitt;   Charite University, Berlin, Germany;   Janssen-Cilag Ltd.
  Recruiting
• CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma

  NCT03287817

  Conditions:   Diffuse Large B Cell Lymphoma;   Relapsed Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   DLBCL
  Intervention:   Biological: AUTO3
  Sponsor:   Autolus Limited
  Recruiting
• In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy

  NCT01976585

  Condition:   Low-Grade B-cell Lymphoma
  Interventions:   Drug: rhuFlt3L/CDX-301;   Drug: Poly-ICLC
  Sponsors:   Joshua Brody;   Celldex Therapeutics
  Recruiting
• Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs

  NCT03346642

  Condition:   Primary Mediastinal Large B-cell Lymphoma
  Interventions:   Drug: Decitabine;   Drug: GVD chemotherapy;   Drug: SHR-1210
  Sponsor:   Chinese PLA General Hospital
  Recruiting
• Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL

  NCT03259529

  Condition:   Diffuse Large B Cell Lymphoma
  Interventions:   Drug: Bendamustine hydrochloride;   Drug: Gemcitabine 500 mg;   Drug: Gemcitabine 700 mg;   Drug: Gemcitabine 1000 mg;   Drug: Nivolumab;   Drug: Rituximab
  Sponsor:   St. Petersburg State Pavlov Medical University
  Recruiting
• Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma

  NCT03656835

  Conditions:   Diffuse Large B-Cell Lymphoma;   Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   High Grade B-Cell Lymphoma
  Intervention:   Procedure: Molecular Nanotechnology
  Sponsors:   Ohio State University Comprehensive Cancer Center;   National Cancer Institute (NCI)
  Recruiting
• Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

  NCT03072771

  Condition:   Diffuse Large B Cell Lymphoma
  Interventions:   Drug: Blinatumomab;   Procedure: Autologous stem cell transplant;   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Melphalan;   Procedure: Peripheral blood draws
  Sponsors:   Washington University School of Medicine;   Amgen
  Recruiting
• A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

  NCT02734771

  Condition:   Diffuse Large B-Cell Lymphoma
  Interventions:   Drug: Brentuximab vedotin;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Prednisone
  Sponsors:   Patrick Reagan;   Seattle Genetics, Inc.
  Recruiting
• Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL

  NCT03305445

  Conditions:   Relapsed Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
  Interventions:   Drug: Ipilimumab;   Drug: Nivolumab
  Sponsors:   Icahn School of Medicine at Mount Sinai;   Bristol-Myers Squibb
  Recruiting
• Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma

  NCT04113226

  Conditions:   Chemotherapy;   Diffuse Large B-Cell Lymphoma (DLBCL), Nos;   Elderly
  Interventions:   Drug: Rituximab;   Drug: Lenalidomide 20 MG;   Other: Comprehensive Geriatric Assessment (CGA);   Other: Activities of daily living (ADL) scale
  Sponsors:   Centre Hospitalier Universitaire, Amiens;   cimiez hospital Nice;   Institut Bergonié;   groupe hospitalier public sud de l'oise;   Henri Mondor University Hospital;   Centre Henri Becquerel;   Hôpital Charles Foix;   Saint-Louis Hospital, Paris, France
  Not yet recruiting
• Treatment for Advanced B-Cell Lymphoma

  NCT01859819

  Conditions:   Diffuse Large Cell Lymphoma;   Burkitt's Lymphoma;   High Grade B-cell Lymphoma
  Interventions:   Drug: Rituximab;   Drug: IT Cytarabine
  Sponsor:   New York Medical College
  Recruiting
• Lenalidomide Based Immunotherapy in the Treatment of DLBCL

  NCT03715296

  Condition:   Diffuse Large B Cell Lymphoma
  Intervention:   Drug: Lenalidomide 25mg
  Sponsor:   Ruijin Hospital
  Recruiting
• Lenalidomide Monotherapy in R/R DLBCL

  NCT04150328

  Condition:   Diffuse Large B Cell Lymphoma
  Intervention:  
  Sponsor:   MorphoSys AG
  Recruiting
• Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL

  NCT03949062

  Condition:   Diffuse Large B Cell Lymphoma
  Interventions:   Drug: Ibrutinib;   Drug: Lenalidomide;   Drug: Rituximab
  Sponsor:   Ruijin Hospital
  Recruiting
• A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

  NCT03136497

  Conditions:   Relapsed Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
  Interventions:   Drug: ABT-199;   Drug: Ibrutinib;   Drug: Rituximab
  Sponsors:   Hackensack Meridian Health;   Janssen Scientific Affairs, LLC;   Genentech, Inc.
  Recruiting
• Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance

  NCT03311958

  Condition:   Diffuse Large B Cell Lymphoma
  Intervention:   Drug: Nivolumab, IV, 240 mg
  Sponsor:   Fox Chase Cancer Center
  Recruiting
• Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL

  NCT04134936

  Condition:   Diffuse Large B-cell Lymphoma
  Interventions:   Drug: Tafasitamab;   Drug: Tafasitamab plus Lenalidomide
  Sponsor:   MorphoSys AG
  Recruiting
• Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226)

  NCT03639181

  Condition:   B-cell Non-Hodgkin's Lymphoma
  Intervention:   Biological: GB226
  Sponsor:   Genor Biopharma Co., Ltd.
  Recruiting
• Chidamide With R-CHOP Regimen for DLBCL Patients

  NCT03201471

  Condition:   Diffuse Large B Cell Lymphoma
  Intervention:   Drug: Chidamide + R-CHOP regimen
  Sponsor:   First Affiliated Hospital of Zhejiang University
  Recruiting
• Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™

  NCT03263026

  Condition:   Diffuse Large B-Cell Lymphoma
  Interventions:   Drug: Enzastaurin Hydrochloride;   Other: R-CHOP + placebo
  Sponsor:   Denovo Biopharma LLC
  Recruiting
• A Study of HMPL-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms

  NCT02857998

  Condition:   Mature B-cell Neoplasms
  Intervention:   Drug: HMPL-523
  Sponsor:   Hutchison Medipharma Limited
  Recruiting
• A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma

  NCT03671018

  Condition:   B-cell Non-Hodgkin Lymphoma
  Interventions:   Drug: Mosunetuzumab;   Drug: Polatuzumab vedotin;   Drug: Rituximab;   Drug: Bendamustine;   Drug: Tocilizumab
  Sponsor:   Hoffmann-La Roche
  Recruiting
• Reduced Chemotherapy in Low Risk DLBCL

  NCT02752815

  Condition:   Diffuse Large B-cell Lymphoma
  Interventions:   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Epirubicin;   Drug: Vincristine;   Drug: Prednisone
  Sponsor:   Ruijin Hospital
  Recruiting
• The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma

  NCT04169932

  Conditions:   Relapsed and Refractory B Cell Lymphoma;   Non-Hodgkin Lymphoma
  Intervention:   Biological: CD20 CAR-T
  Sponsor:   Shanghai Longyao Biotechnology Inc., Ltd.
  Recruiting
• A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

  NCT03677141

  Condition:   B-cell Non-Hodgkin Lymphoma
  Interventions:   Drug: Mosunetuzumab;   Drug: Polatuzumab Vedotin;   Drug: Rituxumab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone;   Drug: Tocilizumab
  Sponsor:   Hoffmann-La Roche
  Recruiting
• Bortezomib Maintenance in High Risk DLBCL

  NCT01965977

  Condition:   Diffuse Large B Cell Lymphoma
  Intervention:   Drug: Bortezomib
  Sponsors:   Samsung Medical Center;   Janssen, LP
  Recruiting
• Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

  NCT03719989

  Conditions:   Diffuse Large B Cell Lymphoma;   Relapsed Non Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma
  Intervention:   Drug: azacitidine plus R-GDP
  Sponsor:   Seoul National University Hospital
  Not yet recruiting
• Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma

  NCT03484819

  Conditions:   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
  Interventions:   Drug: Copanlisib;   Drug: Copanlisib Hydrochloride;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)

  NCT02658968

  Conditions:   Relapsed, Diffuse Large B-cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
  Intervention:   Drug: Betalutin
  Sponsor:   Nordic Nanovector
  Recruiting
• QUILT 3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma

  NCT04052061

  Conditions:   Diffuse Large B Cell Lymphoma;   Large-cell Lymphoma;   Lymphoma, B-Cell;   Lymphoma
  Intervention:   Biological: CD19 t-haNK
  Sponsor:   NantKwest, Inc.
  Not yet recruiting
• RICE-ibrutinib in Relapsed DLBCL

  NCT02955628

  Conditions:   Diffuse Large B Cell Lymphoma;   Diffuse Large B-Cell Lymphoma Recurrent
  Intervention:   Drug: Ibrutinib-RICE
  Sponsors:   Singapore General Hospital;   Janssen, LP
  Recruiting
• Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

  NCT04094142

  Condition:   Non-hodgkin Lymphoma,B Cell
  Intervention:   Drug: Acalabrutinib
  Sponsor:   Seoul National University Hospital
  Recruiting
• A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma

  NCT03571568

  Condition:   Indolent B-Cell Non-Hodgkin Lymphoma
  Intervention:   Biological: BI1206
  Sponsor:   BioInvent International AB
  Recruiting
• Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma

  NCT04067414

  Conditions:   Diffuse Large B Cell Lymphoma;   High-grade B-cell Lymphoma;   Transformed Lymphoma;   Primary Mediastinal Large B Cell Lymphoma
  Intervention:   Biological: BZ019
  Sponsors:   Institute of Hematology & Blood Diseases Hospital;   Shanghai Cell Therapy Engineering Technology Research Center Group Co., Ltd.
  Recruiting
• Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients

  NCT03850028

  Condition:   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  Intervention:   Other: 89Zr-atezolizumab PET scans
  Sponsors:   University Medical Center Groningen;   VU University Medical Center;   Stichting Hemato-Oncologie voor Volwassenen Nederland;   Hoffmann-La Roche
  Recruiting
• First-line Antibiotic Therapy for Early-stage HP(+) Gastric Pure DLBCL

  NCT02388581

  Condition:   Gastric Diffuse Large B-cell Lymphoma
  Intervention:   Drug: Lansoprazole, Amoxicillin, Clarithromycin, Metronidazole
  Sponsors:   National Health Research Institutes, Taiwan;   National Taiwan University Hospital;   Mackay Memorial Hospital;   China Medical University Hospital;   Taichung Veterans General Hospital;   Changhua Christian Hospital;   National Cheng-Kung University Hospital;   Chang Gung Memorial Hospital;   Kaohsiung Medical University
  Recruiting
• Rituximab and Pembrolizumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

  NCT03401853

  Conditions:   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Biological: Rituximab
  Sponsors:   University of Washington;   National Cancer Institute (NCI)
  Recruiting
• Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda

  NCT03864419

  Conditions:   Burkitt Lymphoma;   KSHV-associated Multicentric Castleman Disease;   Diffuse Large B-Cell Lymphoma
  Interventions:   Biological: Rituximab or Rituximab Hyaluronidase Human;   Drug: Cyclophosphamide;   Drug: Vincristine;   Drug: Methotrexate;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Prednisone;   Drug: Etoposide
  Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
  Recruiting
• A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL

  NCT04049825

  Condition:   Relapsed or Refractory Diffuse Large B-cell Lymphoma
  Intervention:   Drug: OPB-111077
  Sponsor:   Otsuka Pharmaceutical Co., Ltd.
  Recruiting
• PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma

  NCT03488251

  Conditions:   Non-hodgkin Lymphoma,B Cell;   Refractory Diffuse Large B-Cell Lymphoma;   Relapsed Diffuse Large B-Cell Lymphoma
  Intervention:   Drug: MT-3724
  Sponsor:   Molecular Templates, Inc.
  Recruiting
• Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

  NCT04002947

  Conditions:   Diffuse Large B-Cell Lymphoma;   Non Hodgkin's Lymphoma;   DLBCL;   NHL
  Interventions:   Drug: DA-EPOCH;   Biological: Rituximab;   Drug: CHOP;   Drug: Acalabrutinib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma

  NCT03571828

  Conditions:   Diffuse Large B-cell Lymphoma(DLBCL);   Mantle Cell Lymphoma (MCL);   Follicular Lymphoma (FL)
  Intervention:   Drug: AMG 562
  Sponsor:   Amgen
  Recruiting
• Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab (KEYNOTE-348)

  NCT03340766

  Condition:   Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
  Interventions:   Drug: Blinatumomab;   Drug: Pembrolizumab
  Sponsors:   Amgen;   Merck Sharp & Dohme Corp.
  Recruiting
• OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine

  NCT01478542

  Condition:   CD20+ Aggressive B-Cell Lymphoma
  Interventions:   Drug: Conventional Vincristine;   Drug: Liposomal Vincristine;   Drug: Ricover-scheme rituximab;   Drug: optimised rituximab-schedule
  Sponsors:   University Hospital, Saarland;   German High-Grade Non-Hodgkin's Lymphoma Study Group;   Spectrum Pharmaceuticals, Inc
  Recruiting
• Study to Evaluate the Efficacy and Tolerability Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory DLBCL and Other Forms of NHL

  NCT02564744

  Conditions:   Diffuse Large B-Cell Lymphoma;   B-cell Non-Hodgkin's Lymphoma
  Interventions:   Drug: Debio 1562;   Drug: Rituximab
  Sponsor:   Debiopharm International SA
  Recruiting
• ENABLE (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)

  NCT04049513

  Conditions:   Lymphomas Non-Hodgkin's B-Cell;   Diffuse Large B-cell Lymphoma (DLBCL);   Primary Mediastinal B-cell Lymphoma (PMBCL);   Transformed Follicular Lymphoma (TFL);   Follicular Lymphoma (FL);   Mantle Cell Lymphoma (MCL)
  Interventions:   Biological: WZTL002-1 (1928T2z CAR-T cells);   Drug: Cyclophosphamide and Fludarabine lymphodepleting chemotherapy
  Sponsors:   Malaghan Institute of Medical Research;   Wellington Zhaotai Therapies Limited
  Recruiting
• PK,PD, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003)

  NCT03645395

  Conditions:   Non-hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Relapsed Diffuse Large B-Cell Lymphoma
  Intervention:   Drug: MT-3724
  Sponsor:   Molecular Templates, Inc.
  Recruiting
• Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)

  NCT03990961

  Conditions:   Diffuse Large B Cell Lymphoma;   Lymphoma
  Intervention:   Drug: Pembrolizumab
  Sponsors:   University of Chicago;   Merck Sharp & Dohme Corp.
  Recruiting
• A Study of RO7082859 in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Non-Hodgkin Lymphomas and Participants With DLBCL

  NCT03467373

  Conditions:   B-Cell Lymphoma;   Non-Hodgkin Lymphoma
  Interventions:   Drug: RO7082859;   Drug: Obinutuzumab (G);   Drug: Rituximab (R);   Drug: Tocilizumab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone
  Sponsor:   Hoffmann-La Roche
  Recruiting
• Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection

  NCT02836925

  Conditions:   Indolent B-cell Lymphoma;   Hepatitis C
  Interventions:   Drug: Ledipasvir+Sofosbuvir;   Drug: Sofosbuvir+Velpatasvir
  Sponsor:   Fondazione Italiana Linfomi ONLUS
  Recruiting
• Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study

  NCT03244176

  Condition:   Lymphomas Non-Hodgkin's B-Cell
  Intervention:   Drug: Avelumab
  Sponsors:   Austin Health;   Merck KGaA, Darmstadt, Germany
  Recruiting
• Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

  NCT03223610

  Conditions:   Lymphoma;   Non-Hodgkin Lymphoma;   Diffuse Large B-Cell Lymphoma;   Burkitt Lymphoma
  Interventions:   Drug: Venetoclax;   Drug: Ibrutinib;   Drug: Prednisone;   Drug: Obinutuzumab;   Drug: Revlimid (lenalidomide)
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Tolerance and Pharmacokinetics of SHR1459 in Patients With Recurrent Replased/Refractory Mature B Cell Neoplasmstumor

  NCT03664297

  Condition:   Mature B Cell Neoplasms
  Intervention:   Drug: SHR1459
  Sponsor:   Jiangsu HengRui Medicine Co., Ltd.
  Recruiting
• Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma

  NCT04156828

  Conditions:   Grade 3b Follicular Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Non-Hodgkin's Lymphoma
  Interventions:   Drug: Copanlisib;   Drug: Gemcitabine;   Drug: Carboplatin;   Drug: Dexamethasone;   Biological: Rituximab;   Biological: Pegfilgrastim
  Sponsors:   University of Washington;   National Cancer Institute (NCI);   Bayer
  Not yet recruiting
• R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL

  NCT04152577

  Condition:   Lymphoma, B-Cell
  Interventions:   Drug: R2-combination chemotherapy;   Drug: R-combination chemotherapy
  Sponsor:   Shandong Provincial Hospital
  Recruiting
• Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy

  NCT03422523

  Conditions:   Diffuse Large B Cell Lymphoma;   Relapsed Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
  Interventions:   Drug: Atezolizumab;   Drug: Rituximab;   Drug: Gemcitabine 1000 mg;   Drug: Oxaliplatin 100 MG
  Sponsors:   University Hospital Southampton NHS Foundation Trust;   Hoffmann-La Roche
  Recruiting
• Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma

  NCT03742258

  Conditions:   Diffuse Large B-Cell Lymphoma;   Diffuse Large B-Cell Lymphoma Activated B-Cell Type;   Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements;   High Grade B-Cell Lymphoma, Not Otherwise Specified;   T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
  Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Prednisone;   Biological: Rituximab;   Drug: Spleen Tyrosine Kinase Inhibitor TAK-659;   Drug: Vincristine Sulfate
  Sponsors:   Northwestern University;   National Cancer Institute (NCI)
  Recruiting
• A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects

  NCT03483688

  Condition:   B-cell Non-Hodgkin Lymphoma
  Intervention:   Biological: CD19-directed CAR-T cells
  Sponsors:   Peking Union Medical College Hospital;   Cellular Biomedicine Group Ltd.
  Not yet recruiting
• Marginal Zone Lymphoma Cohort in Korea

  NCT02732236

  Condition:   Lymphoma, B-Cell, Marginal Zone
  Intervention:   Other: Rituximab
  Sponsor:   Dong-A University Hospital
  Recruiting
• Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas

  NCT03255018

  Conditions:   Non-Hodgkin Lymphoma;   Lymphoma;   Diffuse Large B-Cell Lymphoma;   Gray Zone Lymphoma;   Primary Central Nervious System Lymphoma
  Intervention:   Biological: Pembrolizumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

  NCT03309878

  Conditions:   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent High Grade B-Cell Lymphoma;   Recurrent Transformed B-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory High Grade B-Cell Lymphoma;   Refractory Transformed B-cell Non-Hodgkin Lymphoma
  Interventions:   Biological: Mogamulizumab;   Biological: Pembrolizumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• FT516 in Subjects With Advanced Hematologic Malignancies

  NCT04023071

  Conditions:   Acute Myelogenous Leukemia;   B-cell Lymphoma
  Interventions:   Drug: FT516;   Drug: Rituximab;   Drug: Obinutuzumab;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: IL-2
  Sponsor:   Fate Therapeutics
  Recruiting
• Toripalimab in Combination With R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma

  NCT04058470

  Conditions:   Diffuse Large B Cell Lymphoma;   High-grade B-cell Lymphoma;   Follicular Lymphoma Grade IIIb;   Transformed Lymphoma;   EBV-Positive DLBCL, Nos;   ALK-Positive Anaplastic Large Cell Lymphoma
  Interventions:   Drug: Toripalimab;   Drug: R-CHOP Protocol
  Sponsor:   Huiqiang Huang
  Not yet recruiting
• Safety and Antitumor Activity Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma

  NCT03684694

  Conditions:   Diffuse Large B-Cell Lymphoma;   Mantle Cell Lymphoma
  Intervention:   Drug: Loncastuximab Tesirine and Ibrutinib
  Sponsor:   ADC Therapeutics S.A.
  Recruiting
• Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma

  NCT03939026

  Conditions:   Relapsed/Refractory Large B Cell Lymphoma;   Relapsed/Refractory Follicular Lymphoma
  Interventions:   Genetic: ALLO-501;   Biological: ALLO-647;   Drug: Fludarabine;   Drug: Cyclophosphamide
  Sponsor:   Allogene Therapeutics
  Recruiting
• Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma

  NCT01959698

  Conditions:   CD20 Positive;   Recurrent Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Stage I Diffuse Large B-Cell Lymphoma;   Stage II Diffuse Large B-Cell Lymphoma;   Stage III Diffuse Large B-Cell Lymphoma;   Stage IV Diffuse Large B-Cell Lymphoma
  Interventions:   Drug: Carboplatin;   Drug: Carfilzomib;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Biological: Rituximab
  Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI);   Amgen
  Recruiting
• Atezolizumab, Gemcitabine, Oxaliplatin, and Rituximab in Treating Patients With Relapsed or Refractory Transformed Diffuse Large B-Cell Lymphoma

  NCT03321643

  Conditions:   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Transformed Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Transformed Non-Hodgkin Lymphoma;   Richter Syndrome;   Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
  Interventions:   Drug: Atezolizumab;   Drug: Gemcitabine;   Other: Laboratory Biomarker Analysis;   Drug: Oxaliplatin;   Biological: Rituximab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas

  NCT02633111

  Conditions:   B-cell Non-Hodgkin Lymphoma;   Aggressive
  Interventions:   Other: collected at pre-treatment tumor biopsy;   Other: Peripheral blood tests;   Device: PET/CT
  Sponsors:   Memorial Sloan Kettering Cancer Center;   Mayo Clinic;   M.D. Anderson Cancer Center;   University of Pennsylvania;   University of Miami
  Recruiting
• A Phase II Study of the FIL on Elderly Frail Patients With DLBCL

  NCT02955823

  Condition:   Diffuse Large B-cells Non-Hodgkin Lymphoma
  Intervention:   Drug: Rituximab-Dexamethasone-Lenalidomide
  Sponsor:   Fondazione Italiana Linfomi ONLUS
  Recruiting
• A Trial of Radiotherapy and Durvalumab in DLBCL and FL

  NCT03610061

  Conditions:   Diffuse Large B Cell Lymphoma;   Follicular Lymphoma
  Interventions:   Drug: Durvalumab;   Radiation: Radiotherapy
  Sponsors:   Austin Health;   Olivia Newton-John Cancer Research Institute;   AstraZeneca
  Recruiting
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

  NCT04045028

  Conditions:   Multiple Myeloma;   Non-Hodgkin Lymphoma;   B-Cell Lymphoma
  Interventions:   Drug: Tiragolumab;   Drug: Daratumumab;   Drug: Rituximab
  Sponsor:   Genentech, Inc.
  Recruiting
• A National Study for Blood Based Response Monitoring of B-cell Lymphoma Patients

  NCT04139252

  Condition:   NHL
  Intervention:   Other: No intervention
  Sponsor:   Stichting Hemato-Oncologie voor Volwassenen Nederland
  Not yet recruiting
• Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas

  NCT03161054

  Condition:   Aggressive Non-Hodgkin Lymphoma
  Interventions:   Drug: Prednisone;   Drug: Vinorelbine;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Rituximab
  Sponsor:   Fondazione Italiana Linfomi ONLUS
  Recruiting
• Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma

  NCT03207178

  Condition:   Recurrent or Refractory B Cell Malignancy
  Intervention:   Biological: Mixed CD19/CD20 CAR-T Transfer
  Sponsors:   Shanghai Longyao Biotechnology Inc., Ltd.;   Xuzhou Medical University;   Shanghai Jiao Tong University School of Medicine
  Recruiting
• Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

  NCT03440567

  Conditions:   CCND1 Positive;   CD20 Positive;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Mantle Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Mantle Cell Lymphoma;   Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
  Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Avelumab;   Drug: Carboplatin;   Drug: Etoposide Phosphate;   Drug: Ibrutinib;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Biological: Rituximab;   Biological: Utomilumab
  Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
  Recruiting
• A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies

  NCT03757000

  Conditions:   B-cell Lymphoma Recurrent;   B-cell Chronic Lymphocytic Leukemia
  Intervention:   Drug: YY-20394
  Sponsor:   Shanghai YingLi Pharmaceutical Co. Ltd.
  Recruiting
• R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma

  NCT02628405

  Conditions:   CD20 Positive;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Recurrent Transformed Non-Hodgkin Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Transformed Non-Hodgkin Lymphoma
  Interventions:   Drug: Carboplatin;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Biological: Rituximab
  Sponsors:   Academic and Community Cancer Research United;   National Cancer Institute (NCI)
  Recruiting
• GEN3013 (DuoBody®-CD3xCD20) Safety Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

  NCT03625037

  Conditions:   Diffuse Large B-cell Lymphoma;   High-grade B-cell Lymphoma;   Primary Mediastinal Large B-cell Lymphoma;   Follicular Lymphoma;   Mantle Cell Lymphoma;   Small Lymphocytic Lymphoma;   Marginal Zone Lymphoma
  Intervention:   Biological: GEN3013 (DuoBody®-CD3xCD20)
  Sponsor:   Genmab
  Recruiting
• Thalidomide Combined With R-CHOP in Newly Diagnosed，Untreated Double-expressor Diffuse Large B-Cell Lymphoma Patients

  NCT03318835

  Condition:   Thalidomide
  Interventions:   Drug: Thalidomide combined with R-CHOP;   Drug: R-CHOP
  Sponsor:   Fudan University
  Recruiting
• Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

  NCT03373019

  Conditions:   Chidamide;   Lymphoma, B-Cell;   Lymphoma, Large B-Cell, Diffuse;   Neoplasm by Histology;   Neoplasms;   Lymphoproliferative Disorders;   Lymphatic Diseases;   Immunoproliferative Disorders;   Immune System Diseases;   Lymphoma, Non-Hodgkin;   Cyclophosphamide;   Rituximab;   Gemcitabine;   Cisplatin;   Dexamethasone;   HDAC Inhibitor
  Intervention:   Drug: Chidamide combined with R-GDP
  Sponsor:   Fudan University
  Recruiting
• MC-19PD1 CAR-T in Relapsed or Refractory B Cell Lymphoma

  NCT03932955

  Condition:   Lymphoma
  Intervention:   Biological: MC-19PD1 CAR-T cells
  Sponsor:   Peking University
  Recruiting
• Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

  NCT03696784

  Conditions:   Lymphoma;   Lymphoma, B-Cell;   Immune System Diseases;   Immunoproliferative Disorders;   Lymphatic Diseases
  Interventions:   Biological: iC9-CAR19 T cells;   Drug: Bendamustine;   Drug: Fludarabine;   Drug: AP1903
  Sponsors:   UNC Lineberger Comprehensive Cancer Center;   Bellicum Pharmaceuticals;   V Foundation
  Recruiting
• Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment

  NCT03505762

  Condition:   B-Cell Non-Hodgkin Lymphoma
  Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Biological: Rituximab;   Drug: Vincristine Sulfate
  Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
  Recruiting
• Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma

  NCT03540303

  Condition:   Relapsed Non Hodgkin Lymphoma
  Intervention:   Drug: CAR19 T cells carrying cytoplasmic activated PD-1
  Sponsors:   Henan Cancer Hospital;   The Pregene (ShenZhen) Biotechnology Company, Ltd.
  Recruiting
• CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma

  NCT03579927

  Conditions:   CD19 Positive;   Mantle Cell Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma
  Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Melphalan;   Biological: Rituximab;   Biological: Umbilical Cord Blood-derived Natural Killer Cells
  Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
  Not yet recruiting
• CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma

  NCT03118180

  Condition:   Lymphoma
  Intervention:   Biological: CD19 targeted chimeric antigen receptor T cells
  Sponsors:   Zhejiang University;   Innovative Cellular Therapeutics Co., Ltd.
  Recruiting
• Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)

  NCT03964090

  Conditions:   Central Nervous System Lymphoma;   Secondary Central Nervous System Lymphoma
  Interventions:   Drug: TEDD-R;   Drug: TEDDI-R;   Drug: Ibrutinib;   Drug: Cytarabine;   Drug: Isavuconazole
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

  NCT03038672

  Conditions:   ALK-Positive Large B-Cell Lymphoma;   Atypical Burkitt/Burkitt-Like Lymphoma;   Burkitt-Like Lymphoma With 11q Aberration;   Diffuse Large B-Cell Lymphoma Activated B-Cell Type;   Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation;   Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   EBV-Positive Mucocutaneous Ulcer;   High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements;   High Grade B-Cell Lymphoma, Not Otherwise Specified;   Human Herpesvirus 8-Positive Neoplastic Cells Present;   Intravascular Large B-Cell Lymphoma;   Large B-Cell Lymphoma With IRF4 Rearrangement;   Plasmablastic Lymphoma;   Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type;   Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System;   Primary Effusion Lymphoma;   Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Lymphomatoid Granulomatosis;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Burkitt Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Small Intestinal High Grade B-Cell Lymphoma, Not Otherwise Specified;   T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
  Interventions:   Biological: Nivolumab;   Drug: Varlilumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia

  NCT02933320

  Conditions:   B-cell Lymphoma;   Chronic Lymphocytic Leukaemia;   Waldenström Macroglobulinaemia
  Interventions:   Biological: BI-1206 single agent dose escalation phase;   Biological: BI-1206 single agent expansion phase;   Biological: Combination of BI-1206 with Rituximab
  Sponsor:   Cancer Research UK
  Recruiting
• A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations

  NCT03793140

  Conditions:   Lymphoma;   Leukemia
  Intervention:   Drug: CPI-613
  Sponsors:   Memorial Sloan Kettering Cancer Center;   City of Hope Medical Center;   Massachusetts General Hospital;   M.D. Anderson Cancer Center;   George Washington University
  Recruiting
• Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma.

  NCT04023916

  Conditions:   Diffuse Large B-Cell Lymphoma;   Sintilimab;   TP53 Mutation
  Intervention:   Drug: Sintilimab-R-CHOP
  Sponsor:   Chinese Academy of Medical Sciences
  Not yet recruiting
• B001 in Patients With CD20 Positive B-cell Non Hodgkin's Lymphoma

  NCT03332121

  Condition:   CD20 Positive B Cell Non-Hodgkin's Lymphoma
  Intervention:   Biological: B001
  Sponsor:   Shanghai Pharmaceuticals Holding Co., Ltd
  Recruiting
• Pembrolizumab and Vorinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma

  NCT03150329

  Conditions:   Grade 3b Follicular Lymphoma;   Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma;   Recurrent Classic Hodgkin Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3a Follicular Lymphoma;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Recurrent Transformed Non-Hodgkin Lymphoma;   Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma;   Refractory Classic Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Transformed Non-Hodgkin Lymphoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Drug: Vorinostat
  Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
  Recruiting
• Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma

  NCT03189836

  Condition:   Lymphoma
  Interventions:   Biological: ACTR707;   Biological: rituximab
  Sponsor:   Unum Therapeutics Inc.
  Recruiting
• A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)

  NCT03571308

  Condition:   Non Hodgkin Lymphoma
  Intervention:   Drug: R-CHOP + acalabrutinib
  Sponsor:   University Hospital Southampton NHS Foundation Trust
  Recruiting
• A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

  NCT03758989

  Condition:   DLBCL
  Interventions:   Drug: Rituximab Prednisone;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone
  Sponsor:   University of Rochester
  Recruiting
• Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

  NCT02436707

  Condition:   Lymphoma
  Interventions:   Drug: Ibrutinib;   Drug: Rituximab;   Drug: Gemcitabine;   Drug: Dexamethasone;   Drug: Cisplatin;   Drug: Mesna;   Drug: Cyclophosphamide;   Drug: Etoposide;   Drug: G-CSF
  Sponsors:   Canadian Cancer Trials Group;   Janssen, LP;   Roche Pharma AG
  Recruiting
• Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

  NCT02213913

  Conditions:   Adult Grade III Lymphomatoid Granulomatosis;   B-cell Chronic Lymphocytic Leukemia;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Progressive Hairy Cell Leukemia, Initial Treatment;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Small Lymphocytic Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Small Lymphocytic Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Testicular Lymphoma;   Untreated Hairy Cell Leukemia;   Waldenström Macroglobulinemia
  Interventions:   Drug: lenalidomide;   Drug: etoposide;   Drug: prednisone;   Drug: vincristine sulfate;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Biological: rituximab;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
  Sponsors:   University of Chicago;   National Cancer Institute (NCI)
  Recruiting
• Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma

  NCT02494700

  Conditions:   Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma;   Ann Arbor Stage I Grade 1 Follicular Lymphoma;   Ann Arbor Stage I Grade 2 Follicular Lymphoma;   Ann Arbor Stage I Indolent Adult Non-Hodgkin Lymphoma;   Ann Arbor Stage I Mantle Cell Lymphoma;   Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma;   Ann Arbor Stage II Grade 1 Follicular Lymphoma;   Ann Arbor Stage II Grade 2 Follicular Lymphoma;   Ann Arbor Stage II Indolent Adult Non-Hodgkin Lymphoma;   Ann Arbor Stage II Mantle Cell Lymphoma;   Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma;   Ann Arbor Stage III Grade 1 Follicular Lymphoma;   Ann Arbor Stage III Grade 2 Follicular Lymphoma;   Ann Arbor Stage III Indolent Adult Non-Hodgkin Lymphoma;   Ann Arbor Stage III Mantle Cell Lymphoma;   Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Grade 1 Follicular Lymphoma;   Ann Arbor Stage IV Grade 2 Follicular Lymphoma;   Ann Arbor Stage IV Indolent Adult Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Mantle Cell Lymphoma;   Ocular Adnexal Lymphoma;   Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma;   Orbit Lymphoma
  Interventions:   Radiation: External Beam Radiation Therapy;   Drug: Orbital Radiation
  Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
  Recruiting
• Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse

  NCT03356054

  Condition:   DLBCL
  Interventions:   Combination Product: R-DHAP;   Drug: Brentuximab Vedotin
  Sponsor:   Stichting Hemato-Oncologie voor Volwassenen Nederland
  Not yet recruiting
• Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

  NCT04007029

  Conditions:   CD19 Positive;   CD20 Positive;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Mantle Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Small Lymphocytic Lymphoma
  Interventions:   Biological: Chimeric Antigen Receptor T-Cell Therapy;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Biological: Tocilizumab
  Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI);   Parker Institute for Cancer Immunotherapy
  Recruiting
• Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma

  NCT03478514

  Conditions:   Mantle Cell Lymphoma;   B Cell Lymphoma
  Interventions:   Drug: Palbociclib;   Drug: Ibrutinib
  Sponsors:   Alliance Foundation Trials, LLC.;   Pfizer
  Recruiting
• Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma

  NCT03900377

  Condition:   Lymphoma, B-cell, Diffuse
  Intervention:   Drug: SyB L-0501RI
  Sponsor:   SymBio Pharmaceuticals
  Recruiting
• Genomic Evaluation in Patients With Diffuse Large B Cell Lymphoma After First Relapse/Progression

  NCT03977623

  Condition:   Lymphoma, Large B-Cell, Diffuse
  Intervention:  
  Sponsor:   Samsung Medical Center
  Not yet recruiting
• Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.

  NCT03720457

  Conditions:   CD19-positive;   Diffuse Large B-cell Lymphoma;   Follicular Lymphoma
  Intervention:   Drug: Human CD19 targeted T Cells Injection
  Sponsors:   Hrain Biotechnology Co., Ltd.;   Shanghai Zhongshan Hospital
  Recruiting
• Split-Dose R-CHOP for Older Adults With DLBCL

  NCT03943901

  Conditions:   Diffuse Large B Cell Lymphoma;   DLBCL;   Cancer
  Interventions:   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone;   Biological: Pegfilgrastim
  Sponsors:   University of Wisconsin, Madison;   Medical College of Wisconsin
  Not yet recruiting
• Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients

  NCT04164368

  Condition:   Double Expressor Lymphoma
  Intervention:   Drug: Lenalidomide combined with R-CHOP
  Sponsor:   Fudan University
  Recruiting
• Interim FDG PET/CT in Diffuse Large B Cell Lymphoma (DLBCL) Patients

  NCT01357733

  Condition:   Lymphoma, Large B-Cell, Diffuse
  Intervention:   Other: Early interim FDG PET/CT after 1 cycle of R-CHOP
  Sponsor:   The Catholic University of Korea
  Recruiting
• DPX-Survivac and Checkpoint Inhibitor in DLBCL

  NCT03349450

  Conditions:   Adult Diffuse Large Cell Lymphoma;   Recurrent;   Adult Refractory Diffuse Large B-Cell Lymphoma
  Interventions:   Biological: DPX-Survivac;   Biological: Pembrolizumab;   Drug: Cyclophosphamide 50mg
  Sponsors:   Sunnybrook Health Sciences Centre;   ImmunoVaccine Technologies, Inc. (IMV Inc.);   Merck Sharp & Dohme Corp.
  Recruiting
• Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL

  NCT03283137

  Conditions:   CLL;   B-cell Non Hodgkin Lymphoma
  Interventions:   Drug: TGR-1202;   Drug: Pembrolizumab
  Sponsor:   University of Chicago
  Recruiting
• Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma

  NCT00670358

  Condition:   Lymphoma
  Interventions:   Biological: pegfilgrastim;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: lenalidomide;   Drug: prednisone;   Drug: vincristine sulfate;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis
  Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
  Recruiting
• Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma

  NCT02871869

  Condition:   Diffuse, Large B-Cell, Lymphoma
  Interventions:   Drug: vindesine;   Drug: cyclophosphamide;   Drug: Epirubicin;   Drug: prednisone tablets;   Drug: Cinobufacini Tablets;   Drug: Rituximab
  Sponsor:   Xinjiang Medical University
  Recruiting
• Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL

  NCT02362997

  Conditions:   Hodgkin Lymphoma;   Diffuse Large B Cell Lymphoma;   Peripheral T-Cell Lymphoma
  Intervention:   Drug: Pembrolizumab
  Sponsors:   Dana-Farber Cancer Institute;   Merck Sharp & Dohme Corp.
  Recruiting
• Chidamide Combined With Clad/Gem/Bu With AutoSCT in R/R Diffuse Large B Cell Lymphoma

  NCT03151876

  Condition:   Lymphoma
  Interventions:   Drug: Chidamide;   Drug: Cladribine;   Drug: gemcitabine;   Drug: Busulfan;   Procedure: Autologous hematopoietic stem cell transplantation
  Sponsor:   Sichuan University
  Recruiting
• Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL

  NCT03795571

  Conditions:   Diffuse Large B-cell Lymphoma Recurrent;   Diffuse Large B Cell Lymphoma Refractory
  Interventions:   Drug: Rituximab;   Drug: Gemcitabine;   Drug: Oxaliplatin;   Drug: Dexamethasone;   Drug: Lenalidomide Oral Capsule
  Sponsor:   The First Affiliated Hospital with Nanjing Medical University
  Recruiting
• Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma

  NCT03682796

  Conditions:   Lymphoma;   Lymphoma, B-Cell;   Lymphoma, Non-Hodgkin;   Lymphoma, Mantle-Cell;   Lymphoma, Marginal Zone;   Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Follicular
  Intervention:   Drug: TRPH-222
  Sponsor:   Triphase Research and Development III Corp.
  Recruiting
• R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma

  NCT02428751

  Condition:   Lymphoma, Large B-Cell, Diffuse
  Interventions:   Drug: Pegylated liposomal doxorubicin;   Drug: Doxorubicin;   Drug: Rituximab;   Drug: Cyclophophamide;   Drug: Vincristine;   Drug: Prednisone
  Sponsor:   Wenqi Jiang
  Recruiting
• BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCT

  NCT03229616

  Conditions:   Autologous Hematopoietic Stem Cell Transplantation;   Diffuse Large B-cell Lymphoma;   Conditioning
  Interventions:   Drug: Busulfan (BU);   Drug: Cyclophosphamide (CY);   Drug: Etoposide (VP-16)
  Sponsors:   Nanfang Hospital of Southern Medical University;   Guangzhou First People's Hospital;   Zhujiang Hospital;   Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University;   Third Affiliated Hospital, Sun Yat-Sen University;   Peking University People's Hospital
  Recruiting